Multistate models of developmental toxicity: Application to valproic acid-induced malformations in the zebrafish embryo

Adapting classic paradigms to analyze alterations of shoal-wide behavior in early-life stages of zebrafish (Danio rerio) - A case study with fluoxetine

Given the strong increase in prescription of neuroactive pharmaceuticals, neurotoxicity has received growing concern in science and the public. Regulatory requirements stimulated the development of new methods to evaluate the risk of neurotoxic substances for humans and the environment, and, with respect to potential damage to aquatic ecosystems, a variety of behavior-based assays have been proposed for neurotoxicity testing, most of which, however, are restricted to changes in the behavior of individual fish. Since many fish species form shoals under natural conditions, this may cause important aspects of behavior to be overlooked and there is a need for behavior assays integrating individual behavior with behavior of the entire swarm. In order to combine more environmentally realistic sub-chronic exposure scenarios with undistorted social behavior and animal welfare considerations, two behavioral assays are proposed that might be integrated into early-life stage toxicity studies according to OECD TG 210, which are commonly run for a multitude of regulations: To this end, protocols for a novel tank test and a predator response assay were adapted to also record the behavior of free-swimming zebrafish (Danio rerio) juveniles within shoals. Comparisons of the diving response (novel tank) or the shoal's coherence and position relative to the stimulus (predator) with control groups allow conclusions about the anxiety state of the fish, which might well have an impact on survival chances in the wild. As a model substance, the antidepressant fluoxetine ((RS)-N-Methyl-3-phenyl-3-(4-trifluoromethylphenoxy)propylamine) produced adverse effects down to concentrations three orders of magnitude below the EC₁₀ from acute fish embryo toxicity tests according to OECD TG 236. With the integration of such behavior tests into OECD TG 210, important population-relevant information on potential neurotoxicity can be collected without increasing the number of experimental animals.

Toxicokinetic Modeling of Per- and Polyfluoroalkyl Substance Concentrations within Developing Zebrafish (Danio rerio) Populations

Per- and polyfluoroalkyl substances (PFAS) are pervasive environmental contaminants, and their relative stability and high bioaccumulation potential create a challenging risk assessment problem. Zebrafish (Danio rerio) data, in principle, can be synthesized within a quantitative adverse outcome pathway (qAOP) framework to link molecular activity with individual or population level hazards. However, even as qAOP models are still in their infancy, there is a need to link internal dose and toxicity endpoints in a more rigorous way to further not only qAOP models but adverse outcome pathway frameworks in general. We address this problem by suggesting refinements to the current state of toxicokinetic modeling for the early development zebrafish exposed to PFAS up to 120 h post-fertilization. Our approach describes two key physiological transformation phenomena of the developing zebrafish: dynamic volume of an individual and dynamic hatching of a population. We then explore two different modeling strategies to describe the mass transfer, with one strategy relying on classical kinetic rates and the other incorporating mechanisms of membrane transport and adsorption/binding potential. Moving forward, we discuss the challenges of extending this model in both timeframe and chemical class, in conjunction with providing a conceptual framework for its integration with ongoing qAOP modeling efforts.

Structure-Activity Relationship (SAR) Model for Predicting Teratogenic Risk of Antiseizure Medications in Pregnancy by Using Support Vector Machine

Teratogenicity is one of the main concerns in clinical medications of pregnant women. Prescription of antiseizure medications (ASMs) in women with epilepsy during pregnancy may cause teratogenic effects on the fetus. Although large scale epilepsy pregnancy registries played an important role in evaluating the teratogenic risk of ASMs, for most ASMs, especially the newly approved ones, the potential teratogenic risk cannot be effectively assessed due to the lack of evidence. In this study, the analyses are performed on any medication, with a focus on ASMs. We curated a list containing the drugs with potential teratogenicity based on the US Food and Drug Administration (FDA)-approved drug labeling, and established a support vector machine (SVM) model for detecting drugs with high teratogenic risk. The model was validated by using the post-marketing surveillance data from US FDA Spontaneous Adverse Events Reporting System (FAERS) and applied to the prediction of potential teratogenic risk of ASMs. Our results showed that our proposed model outperformed the state-of-art approaches, including logistic regression (LR), random forest (RF) and extreme gradient boosting (XGBoost), when detecting the high teratogenic risk of drugs (MCC and recall rate were 0.312 and 0.851, respectively). Among 196 drugs with teratogenic potential reported by FAERS, 136 (69.4%) drugs were correctly predicted. For the eight commonly used ASMs, 4 of them were predicted as high teratogenic risk drugs, including topiramate, phenobarbital, valproate and phenytoin (predicted probabilities of teratogenic risk were 0.69, 0.60 0.59, and 0.56, respectively), which were consistent with the statement in FDA-approved drug labeling and the high reported prevalence of teratogenicity in epilepsy pregnancy registries. In addition, the structural alerts in ASMs that related to the genotoxic carcinogenicity and mutagenicity, idiosyncratic adverse reaction, potential electrophilic agents and endocrine disruption were identified and discussed. Our findings can be a good complementary for the teratogenic risk assessment in drug development and facilitate the determination of pharmacological therapies during pregnancy.